. . . . "Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin F2alpha analogue. [Wikipedia]"@en . "Travoprost"@en . . "Terminal elimination half-life of travoprost free acid is 45 minutes."@en . . . . . . . . . . "Travatan Z"@en . . . . . . . "Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1e,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate"@en . . . . . . . . . . "Symptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract."@en . . . . . . . "Less than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid."@en . "Systemically absorbed when administered to the eye."@en . . "Humans and other mammals"@en . . . . "Travoprost"@en . "Travatan"@en . . . "Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication."@en . . . . . . . . . . . "Travoprostum"@en . . . "# Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18452763 # Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19929706 # Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9038626 # Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19038618 # Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18983226"@en . "Travoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility."@en . . " "@en . . "157283-68-6"@en . . . . . . . . "approved"@en . .